Inebilizumab (anti-CD19) has been approved for the treatment of neuromyelitis optica spectrum disorder (NMOSD) [8], and a clinical trial on the efficacy of inebilizumab in MG (MINT; ClinicalTrials.gov Identifier: NCT04524273) is currently ongoing. Here, CD19 is linked to myasthenia gravis.